Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:CLVS
- CUSIP: 18946410
- Web: www.clovisoncology.com
Capitalization:- Market Cap: $3.52 billion
- Outstanding Shares: 48,879,000
Average Prices:- 50 Day Moving Avg: $83.40
- 200 Day Moving Avg: $67.51
- 52 Week Range: $16.61 - $99.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -31.20
- P/E Growth: 0.11
Sales & Book Value:- Annual Revenue: $21.74 million
- Price / Sales: 162.06
- Book Value: $7.04 per share
- Price / Book: 10.24
Profitability:- EBIDTA: ($242,160,000.00)
- Return on Equity: -177.30%
- Return on Assets: -47.13%
Debt:- Debt-to-Equity Ratio: 0.82%
- Current Ratio: 3.26%
- Quick Ratio: 3.23%
Misc:- Average Volume: 1.94 million shs.
- Beta: 1.53
- Short Ratio: 4.95
Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology, Inc. (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($1.29) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by $0.02. The business earned $14.62 million during the quarter, compared to analysts' expectations of $13.07 million. Clovis Oncology's quarterly revenue was down 32.5% on a year-over-year basis. During the same quarter last year, the company posted ($2.07) earnings per share. View Clovis Oncology's Earnings History.
When will Clovis Oncology make its next earnings announcement?
Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?
17 analysts have issued 12-month price targets for Clovis Oncology's stock. Their predictions range from $23.00 to $125.00. On average, they anticipate Clovis Oncology's share price to reach $79.53 in the next year. View Analyst Ratings for Clovis Oncology.
What are analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. Cann analysts commented, "Clovis Oncology and Bristol-Myers Squibb Company announced today that the companies have entered into a clinical collaboration agreement to evaluate the combination of Bristol-Myers Squibb’s immunotherapy Opdivo and Clovis Oncology’s PARP inhibitor Rubraca in pivotal phase III clinical trials in advanced ovarian cancer and triple-negative breast cancers, and a phase II prostate cancer study. All three studies are expected to begin before the end of 2017. Covis will be the study sponsor for the ovarian cancer study and Bristol-Myers Squibb for the prostate and breast cancer studies, with Clovis and Bristol-Myers Squibb sharing equally all trial costs for the breast cancer study." (7/31/2017)
- 2. According to Zacks Investment Research, "Clovis got a huge boost with the FDA granting accelerated approval to its advanced ovarian cancer treatment, Rubraca in Dec 2016. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Successful commercialization will significantly boost Clovis’ sales. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study is expected to help expand Rubraca’s label. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Rubraca is also set to face intense competition from currently marketed PARP inhibitors. Loss estimates have widened lately ahead of the Q2 results. Clovis has a mixed earnings surprise record in the recent quarters." (7/13/2017)
- 3. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
- 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include TESARO (TSRO), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), Axovant Sciences (AXON) and Aerie Pharmaceuticals (AERI).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- M. James E. Barrett Ph.D., Independent Chairman of the Board
- Patrick J. Mahaffy, President, Chief Executive Officer, Director
- Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
- Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
- Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
- C. Dale Hooks, Senior Vice President, Chief Commercial Officer
- Brian G. Atwood, Independent Director
- James C. Blair Ph.D., Independent Director
- Keith T. Flaherty M.D., Independent Director
- Ginger L. Graham, Independent Director
Who owns Clovis Oncology stock?
Clovis Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.11%), Palo Alto Investors LLC (6.81%), PointState Capital LP (4.08%), State Street Corp (3.98%), FMR LLC (3.88%) and Franklin Resources Inc. (3.73%). Company insiders that own Clovis Oncology stock include Erle T Mast, Gillian C Ivers-Read, James C Blair and Lindsey Rolfe. View Institutional Ownership Trends for Clovis Oncology.
Who sold Clovis Oncology stock? Who is selling Clovis Oncology stock?
Clovis Oncology's stock was sold by a variety of institutional investors in the last quarter, including GAM Holding AG, Palo Alto Investors LLC, Versant Venture Management LLC, C WorldWide Group Holding A S, FMR LLC, Westfield Capital Management Co. LP, PDT Partners LLC and Blue Jay Capital Management LLC. Company insiders that have sold Clovis Oncology stock in the last year include Gillian C Ivers-Read and James C Blair. View Insider Buying and Selling for Clovis Oncology.
Who bought Clovis Oncology stock? Who is buying Clovis Oncology stock?
Clovis Oncology's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Franklin Resources Inc., Eagle Asset Management Inc., Farallon Capital Management LLC, Fred Alger Management Inc., Macquarie Group Ltd., Vanguard Group Inc. and Samlyn Capital LLC. View Insider Buying and Selling for Clovis Oncology.
How do I buy Clovis Oncology stock?
Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of Clovis Oncology stock can currently be purchased for approximately $72.08.
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 7 Hold Ratings, 10 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.59) |
| Consensus Price Target: | $79.53 (10.34% upside) |
Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/18/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | | Medium |  |
| 8/18/2017 | Leerink Swann | Lower Price Target | Outperform | $107.00 | High | |
| 8/16/2017 | Evercore ISI | Initiated Coverage | In -> In-Line | $73.00 | High | |
| 8/10/2017 | Morgan Stanley | Reiterated Rating | Overweight | $93.00 | Medium | |
| 8/3/2017 | Bank of America Corporation | Reiterated Rating | Buy | | Low | |
| 7/31/2017 | Cann | Reiterated Rating | Hold | | High | |
| 7/18/2017 | Credit Suisse Group | Set Price Target | Buy | $107.00 | Low | |
| 7/7/2017 | Gabelli | Initiated Coverage | Buy | $125.00 | High | |
| 6/23/2017 | Oppenheimer Holdings, Inc. | Initiated Coverage | Market Perform | | Low | |
| 6/22/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | Low | |
| 6/20/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $67.00 -> $90.00 | High | |
| 6/20/2017 | Janney Montgomery Scott | Upgrade | Neutral -> Buy | | Medium | |
| 6/19/2017 | Stifel Nicolaus | Boost Price Target | Buy | $86.00 -> $125.00 | High | |
| 6/19/2017 | Chardan Capital | Upgrade | Sell -> Neutral | $36.00 -> $50.00 | High | |
| 3/28/2017 | Piper Jaffray Companies | Set Price Target | Buy | $77.00 | Low | |
| 12/21/2016 | WallachBeth Capital | Boost Price Target | Hold | $22.00 -> $49.00 | N/A | |
| 8/24/2016 | Mizuho | Boost Price Target | Neutral | $15.00 -> $23.00 | N/A | |
(Data available from 8/23/2015 forward)
Earnings History for Clovis Oncology (NASDAQ:CLVS)Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($1.18) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($1.27) | ($1.29) | $13.07 million | $14.62 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($1.43) | ($1.33) | $6.04 million | $7.05 million | View | Listen | |
| 2/22/2017 | Q416 | ($1.65) | ($1.83) | | $0.08 million | View | Listen | |
| 11/3/2016 | Q316 | ($1.95) | ($1.70) | | | View | Listen | |
| 8/8/2016 | Q216 | ($2.13) | ($2.07) | | | View | Listen | |
| 5/5/2016 | Q116 | ($2.39) | ($2.17) | | | View | Listen | |
| 2/25/2016 | Q415 | ($2.39) | ($2.23) | | | View | Listen | |
| 11/5/2015 | Q315 | ($2.07) | ($2.62) | | | View | Listen | |
| 8/6/2015 | Q215 | ($2.11) | ($2.10) | $1.17 million | | View | Listen | |
| 5/6/2015 | Q115 | ($1.78) | ($1.86) | $13.60 million | | View | Listen | |
| 2/25/2015 | Q414 | ($1.41) | ($1.62) | | | View | Listen | |
| 11/6/2014 | Q314 | ($1.03) | ($1.17) | | | View | Listen | |
| 8/7/2014 | Q214 | ($0.93) | ($1.03) | | $13.60 million | View | Listen | |
| 5/8/2014 | Q114 | ($0.85) | ($0.91) | | $13.60 million | View | Listen | |
| 2/27/2014 | Q4 | ($0.78) | ($0.92) | | | View | Listen | |
| 10/31/2013 | Q313 | ($0.68) | ($0.68) | | | View | Listen | |
| 8/1/2013 | Q2 2013 | ($0.65) | ($0.72) | | | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.60) | ($0.60) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)2017 EPS Consensus Estimate: ($4.97)
2018 EPS Consensus Estimate: ($2.67)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.53) | ($1.53) | ($1.53) |
| Q2 2017 | 3 | ($1.30) | ($1.18) | ($1.23) |
| Q3 2017 | 3 | ($1.24) | ($1.10) | ($1.15) |
| Q4 2017 | 3 | ($1.12) | ($1.03) | ($1.06) |
| Q1 2018 | 1 | ($0.85) | ($0.85) | ($0.85) |
| Q2 2018 | 1 | ($0.67) | ($0.67) | ($0.67) |
| Q3 2018 | 1 | ($0.64) | ($0.64) | ($0.64) |
| Q4 2018 | 1 | ($0.51) | ($0.51) | ($0.51) |
(Data provided by Zacks Investment Research)
Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 92.80%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $70.05 | $210,150.00 | |
| 8/4/2017 | James C Blair | Director | Sell | 18,450 | $78.61 | $1,450,354.50 | |
| 7/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.56 | $274,680.00 | |
| 6/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $61.82 | $185,460.00 | |
| 5/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $47.39 | $142,170.00 | |
| 4/17/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $56.02 | $168,060.00 | |
| 3/15/2017 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $66.99 | $200,970.00 | |
| 11/2/2015 | Erle T. Mast | CFO | Sell | 3,000 | $105.56 | $316,680.00 | |
| 10/28/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $98.02 | $392,080.00 | |
| 10/15/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $91.91 | $275,730.00 | |
| 10/5/2015 | Lindsey Rolfe | insider | Sell | 4,000 | $93.04 | $372,160.00 | |
| 10/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $90.22 | $270,660.00 | |
| 9/18/2015 | Gillian C Ivers-Read | Insider | Sell | 3,000 | $112.56 | $337,680.00 | |
| 9/1/2015 | Erle T. Mast | CFO | Sell | 3,000 | $79.51 | $238,530.00 | |
| 7/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $85.70 | $257,100.00 | |
| 6/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $88.78 | $266,340.00 | |
| 5/15/2015 | M James Barrett | Director | Sell | 2,424 | $92.43 | $224,050.32 | |
| 4/1/2015 | Erle T Mast | CFO | Sell | 3,000 | $71.25 | $213,750.00 | |
| 3/9/2015 | Erle T Mast | CFO | Sell | 9,000 | $78.84 | $709,560.00 | |
| 3/5/2015 | James C Blair | Director | Sell | 8,528 | $77.70 | $662,625.60 | |
| 1/16/2015 | Steven L Hoerter | Insider | Sell | 10,000 | $67.00 | $670,000.00 | |
| 12/11/2013 | Erle Mast | CFO | Sell | 50,000 | $52.78 | $2,639,000.00 | |
| 12/5/2013 | Thorlef Spickschen | Director | Sell | 9,000 | $56.10 | $504,900.00 | |
| 6/5/2013 | Andrew R Allen | Insider | Sell | 22,594 | $68.54 | $1,548,592.76 | |
| 6/4/2013 | M James Barrett | Director | Sell | 2,483 | $70.80 | $175,796.40 | |
| 6/4/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 159,192 | $64.58 | $10,280,619.36 | |
| 6/4/2013 | Steven L Hoerter | Insider | Sell | 10,000 | $73.06 | $730,600.00 | |
| 3/6/2013 | Parters Vii L P Domain | Major Shareholder | Sell | 250,000 | $24.59 | $6,147,500.00 | |
| 8/16/2012 | Edward J Mckinley | Director | Buy | 9,701 | $15.50 | $150,365.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
| Source: |
|
| Date | Headline |
|---|
 | Ovarian Cancer Market Still Up For Grabs
finance.yahoo.com - August 18 at 5:21 PM |
| Tesaro: Losing It's Edge?
finance.yahoo.com - August 18 at 5:21 PM |
 | Clovis Oncology's (CLVS) Buy Rating Reiterated at J P Morgan Chase & Co
www.americanbankingnews.com - August 18 at 11:22 AM |
| Clovis Oncology, Inc. (CLVS) PT Lowered to $107.00
www.americanbankingnews.com - August 18 at 8:12 AM |
| Clovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : August 17, 2017
finance.yahoo.com - August 16 at 10:45 PM |
| Clovis Oncology, Inc. (CLVS) Now Covered by Analysts at Evercore ISI
www.americanbankingnews.com - August 16 at 6:58 PM |
 | Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses - Nasdaq
www.nasdaq.com - August 16 at 4:02 AM |
| Clovis Oncology, Inc. (CLVS) Insider Sells $210,150.00 in Stock
www.americanbankingnews.com - August 15 at 7:38 PM |
| Clovis (CLVS) Focuses on Label Expansion, Rubraca Impresses
finance.yahoo.com - August 15 at 5:58 PM |
| See what the IHS Markit Score report has to say about Clovis Oncology Inc.
finance.yahoo.com - August 11 at 5:43 PM |
| See what the IHS Markit Score report has to say about Clovis Oncology Inc.
finance.yahoo.com - August 11 at 5:43 PM |
| Clovis Oncology Enters Oversold Territory (CLVS) - Nasdaq
www.nasdaq.com - August 9 at 10:32 PM |
 | A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision - Benzinga
www.benzinga.com - August 9 at 3:07 AM |
| Insider Selling: Clovis Oncology, Inc. (CLVS) Director Sells 18,450 Shares of Stock
www.americanbankingnews.com - August 8 at 7:44 PM |
| Clovis Oncology, Inc. Expected to Post FY2018 Earnings of ($2.60) Per Share (CLVS)
www.americanbankingnews.com - August 7 at 9:30 AM |
| Zacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) Will Post Quarterly Sales of $18.58 Million
www.americanbankingnews.com - August 7 at 7:54 AM |
| Q3 2017 EPS Estimates for Clovis Oncology, Inc. Reduced by Oppenheimer Holdings (NASDAQ:CLVS)
www.americanbankingnews.com - August 7 at 7:09 AM |
| Brokers Issue Forecasts for Clovis Oncology, Inc.'s Q3 2017 Earnings (CLVS)
www.americanbankingnews.com - August 7 at 7:09 AM |
| Clovis Oncology, Inc. to Post Q3 2017 Earnings of ($1.10) Per Share, SunTrust Banks Forecasts (CLVS)
www.americanbankingnews.com - August 7 at 7:08 AM |
| Zacks: Analysts Expect Clovis Oncology, Inc. (NASDAQ:CLVS) Will Post Earnings of -$1.14 Per Share
www.americanbankingnews.com - August 5 at 10:38 PM |
| FY2020 EPS Estimates for Clovis Oncology, Inc. (CLVS) Cut by Analyst
www.americanbankingnews.com - August 4 at 7:58 PM |
| Research Analysts Set Expectations for Clovis Oncology, Inc.'s FY2019 Earnings (CLVS)
www.americanbankingnews.com - August 4 at 7:40 PM |
| Clovis Oncology, Inc. breached its 50 day moving average in a Bearish Manner : CLVS-US : August 4, 2017
finance.yahoo.com - August 4 at 5:35 PM |
| Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses - Nasdaq
www.nasdaq.com - August 4 at 4:52 AM |
| Edited Transcript of CLVS earnings conference call or presentation 2-Aug-17 8:30pm GMT
finance.yahoo.com - August 3 at 6:51 PM |
| Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses
finance.yahoo.com - August 3 at 6:51 PM |
| One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?
finance.yahoo.com - August 3 at 6:51 PM |
| Clovis reports 2Q loss
finance.yahoo.com - August 2 at 11:05 PM |
| Clovis Oncology, Inc. (NASDAQ:CLVS) Issues Earnings Results, Beats Estimates By $0.61 EPS
www.americanbankingnews.com - August 2 at 9:28 PM |
| Investor Network: Clovis Oncology, Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 6:03 PM |
| Clovis Oncology Announces Second Quarter 2017 Operating Results
finance.yahoo.com - August 2 at 6:03 PM |
| Equities Analysts Offer Predictions for Clovis Oncology, Inc.'s Q1 2018 Earnings (NASDAQ:CLVS)
www.americanbankingnews.com - August 2 at 2:38 PM |
| Clovis Oncology, Inc. (NASDAQ:CLVS) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 1 at 10:54 AM |
 | Clovis Sell-Off May Be Overdone - TheStreet.com
www.thestreet.com - August 1 at 3:22 AM |
| Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why - TheStreet.com
www.thestreet.com - July 31 at 10:21 PM |
| Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types
finance.yahoo.com - July 31 at 5:14 PM |
| Bristol-Myers and Clovis will partner for cancer combination trials
finance.yahoo.com - July 31 at 5:14 PM |
| Today's Research Reports on Trending Tickers: Clovis Oncology Inc. and Intercept Pharmaceuticals Inc.
finance.yahoo.com - July 31 at 5:14 PM |
| Discovery, Clovis, Hertz Are Monday's Worst Performing Stocks -- Here's Why
finance.yahoo.com - July 31 at 5:14 PM |
| Why Clovis Oncology Tumbled 13.5% Today
finance.yahoo.com - July 31 at 5:14 PM |
| Clovis Oncology, Inc. (CLVS) Earns "Hold" Rating from Cann
www.americanbankingnews.com - July 31 at 11:08 AM |
| Clovis Oncology, Inc. (NASDAQ:CLVS) PT Set at $107.00 by Credit Suisse Group
www.americanbankingnews.com - July 20 at 12:58 AM |
| Clovis Oncology, Inc. (CLVS) Raised to "Buy" at Vetr Inc.
www.americanbankingnews.com - July 20 at 12:26 AM |
| 3 Stocks at 52-Week Highs Still Worth Buying
finance.yahoo.com - July 18 at 6:48 PM |
| Clovis Oncology, Inc. (NASDAQ:CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares
www.americanbankingnews.com - July 17 at 10:14 PM |
| $13.65 Million in Sales Expected for Clovis Oncology, Inc. (NASDAQ:CLVS) This Quarter
www.americanbankingnews.com - July 16 at 8:00 AM |
| Analysts Expect Clovis Oncology, Inc. (NASDAQ:CLVS) to Post -$1.29 EPS
www.americanbankingnews.com - July 14 at 6:20 PM |
| Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion ... - Nasdaq
www.nasdaq.com - July 14 at 4:26 AM |
| Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion
finance.yahoo.com - July 13 at 6:23 PM |
| Zacks Investment Research Lowers Clovis Oncology, Inc. (NASDAQ:CLVS) to Hold
www.americanbankingnews.com - July 13 at 3:06 PM |
Clovis Oncology (CLVS) Chart for Wednesday, August, 23, 2017
